← FDA DRUG APPROVALS

FDA ANDA · ANDA208430

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA208430
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

LINAGLIPTIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 1GM · TABLET · ORAL
LINAGLIPTIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
LINAGLIPTIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
LINAGLIPTIN 2.5MG, METFORMIN HYDROCHLORIDE 850MG · TABLET · ORAL

Approval history

2018-11-01UNKNOWN · Original · standard — Letter ↗TA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →